Orca-T Diversifies Well-Tolerated Post-Transplant Treatment Options for Hematologic Malignancies | OncLive Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.

Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field. @huntsmancancer.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology
www.onclive.com/view/orca-t-...

Real-World Analysis Reveals Favorable Outcomes With Liso-Cel in Chronic Lymphocytic Leukemia | OncLive Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, 44% CR rate, and manageable safety.

📊Real-World CAR T Data in CLL

New multicenter data show liso-cel delivers strong activity in R/R CLL, with an 85% ORR, rapid responses, and a manageable safety profile.

@astct.bsky.social @cibmtr.bsky.social #Tandem2026 @fredhutch.org @uwmedicine.bsky.social

🔎: www.onclive.com/view/real-wo...

Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL | OncLive Alfonso Molina, MD, MPH, discusses a phase 1 trial evaluating Orca-T with allogeneic CAR T-cell therapy in high-risk B-cell acute lymphoblastic leukemia.

Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL @stanfordmedicine.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology
www.onclive.com/view/orca-t-...

👀 What presentations were most noteworthy from the #Tandem2026? Sign up to read insights from #hematology experts about research expected to propel cell therapy developments! @osucccjames.bsky.social @ohsunews.bsky.social @stanfordmedicine.bsky.social #Oncology
www.onclive.com/view/experts...

Myeloablative Orca-Q Yields High Engraftment Rates in High-Risk Hematologic Malignancies With Haploidentical Donors | OncLive Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.

Myeloablative Orca-Q Yields High Engraftment Rates in High-Risk Hematologic Malignancies With Haploidentical Donors @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #Oncology

www.onclive.com/view/myeloab...

Myeloablative Allo-HCT Improves Long-Term OS in Select Patients With ALL | OncLive Age was correlated with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

Myeloablative Allo-HCT Improves Long-Term OS in Select Patients With #ALL @astct.bsky.social @cibmtr.bsky.social #Tandem2026

www.onclive.com/view/myeloab...

🔊 Listen to this exclusive interview with Dr. James L.M. Ferrara (Icahn School of Medicine at Mount Sinai) on Transplant Radio™ in booth 511 at #Tandem26!

🎧 Listen Now: lnkd.in/gESGm4R8

#agvhd #Tandem2026 #TransplantRADIO

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced #Melanoma @astct.bsky.social @cibmtr.bsky.social #tandem2026

www.onclive.com/view/single-...

📊 Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R #Myeloma 🩸🧬
@astct.bsky.social @cibmtr.bsky.social #Tandem2026

www.onclive.com/view/long-te...

🏆 NMDP is proud to receive the ASTCT Public Service Award at #Tandem2026, with CEO Amy Ronneberg recognized on behalf of our org.

Since 1987, NMDP has advanced transplantation & access to cell therapy—impacting 140,000+ lives. We thank ASTCT for recognizing that commitment with a meaningful honor!

Bridging Therapy Nonresponse, High Lymphocyte Count Are Associated With Parkinsonism After Cilta-Cel in #Myeloma @astct.bsky.social @cibmtr.bsky.social #Tandem2026

www.onclive.com/view/bridgin...

Ustekinumab Plus Standard Prophylaxis Reduces GVHD in MAC Subgroup @astct.bsky.social @cibmtr.bsky.social
#Tandem2026
www.onclive.com/view/ustekin...

TRX103 Tr1 Cell Therapy Shows Manageable Safety ✅ and Dose-Dependent Kinetics 📈 After HLA-Mismatched HCT 🩸 in Hematologic Malignancies 🧬
@astct.bsky.social @cibmtr.bsky.social #Tandem2026

Read the full article ⬇️
www.onclive.com/view/trx103-...

The use of prophylactic dexamethasone did not lower the risk of delayed neurotoxicities in patients with multiple myeloma who received cilta-cel.

Read more on these retrospective data presented at #Tandem2026 #mmsm #oncology www.onclive.com/view/prophyl...

Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD
#oncology #Tandem2026 @astct.bsky.social @cibmtr.bsky.social
www.onclive.com/view/acalabr...

HLA Mismatch Levels Show Comparable Survival, PROs | NMDP NMDP-sponsored ACCESS trial data presented at the 2026 Tandem Meetings show comparable patient-reported outcomes and survival, even for <7/8 matches. Read the results.

🔬 NMDP and CIBMTR are presenting new findings from the ACCESS study at #Tandem2026.

These new findings highlight important dimensions of transplant outcomes and patient experience following mismatched unrelated donor (MMUD) transplantation 👉 go.nmdp.org/Tandem2026

#Tandem26 has begun! Come see us at booth # 511.

🧫 Meet the Scientists of Eurofins Viracor
🎙 Be a guest on Transplant Radio™
🎨 Win a painting from world renowned artist, "Scribe" Donald Ross

#Tandem2026 #gvhd #cartcell

It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️

We have touched down in Salt Lake City for the 2026 Transplantation & Cellular Therapy Meetings! We're gearing up for lots of excitement on the ground for the first day of the meeting today, so stay tuned! @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #hematology
www.onclive.com/conference/tct

As the 2026 Transplantation & Cellular Therapy Meetings approach, Drs Phillips, Dholaria, and Ahmed note the abstracts they’re watching. @astct.bsky.social @cibmtr.bsky.social
#Tandem2026 #leusm #hematology
👉 Sign up to read the full preview: www.onclive.com/view/hematol...

Looking forward to seeing many of you in person and continuing the discussion around immune and cellular therapies.

#Tandem2026 #CellTherapy #GlobalOncology #Grateful #AcademicCollaboration

Tandem Meetings 2026 - Transplantation & Cellular Therapy Meetings | Clinical | Eurofins-Viracor

🔎 Learn about 👉 "Scribe" Donald Ross.
www.scribbleversestudios.com

Eurofins Viacor at Tandem: 👇
www.eurofins-viracor.com/news-and-eve...

#tandem2026 #childrenshospital #pharmD #immunology

The NMDP/CIBMTR community is excited to present featured research at #Tandem2026 next week.

Add these to your calendar to engage with research driving innovation, expanding donor options and improving outcomes for patients.

Join us at #Tandem26 for an interview on Transplant Radio! (Booth # 511) 🎙️ Sit down with our host for a 30 minute discussion and AMPLIFY your influence.

📅 Book your spot: outlook.office.com/book/Transpl...

#TransplantRadio #Tandem2026